CSE:COOL - Post Discussion
Post by
Betteryear2 on Jul 26, 2021 8:26am
Seeks to Revolutionize Treatment of Parkinson’s Disease
VANCOUVER, British Columbia, July 26, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (the “Company”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”) has commenced the development of another breakthrough psychedelic drug formulation, and confirms the filing of another provisional patent application with the United States Patent and Trademark Office (USPTO) under application number 63147338, for the protection of its intellectual property designed to address Parkinson’s Disease, also known as AKO004.
https://www.globenewswire.com/news-release/2021/07/26/2268458/0/en/Core-One-Labs-Akome-Seeks-to-Revolutionize-Treatment-of-Parkinson-s-Disease-and-Submits-Application-to-Protect-IP.html
Be the first to comment on this post